Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anuj Bhargava

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|April 19, 2012
Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial)Bruce S Trippe, Mark D Shepherd, Franklin C Coulter, et al.
The American Journal of Medicine|October 27, 2009
A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial)David S Oyer, Mark D Shepherd, Franklin C Coulter, et al.
Clinical Therapeutics|July 12, 2011
Efficacy and tolerability of self-titrated biphasic insulin aspart 70/30 in patients aged >65 years with type 2 diabetes: an exploratory post hoc subanalysis of the INITIATEplus trialDavid S Oyer, Mark D Shepherd, Franklin C Coulter, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|February 2, 2019
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 TrialLouis Chaykin, Anuj Bhargava, Raymond de la Rosa, et al.
NEJM Evidence|June 23, 2025
Semaglutide in Adults with Type 1 Diabetes and ObesityViral N Shah, Halis K Akturk, Davida Kruger, et al.
Diabetes Technology & Therapeutics|December 14, 2019
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical TrialJames Thrasher, Sarit Polsky, Lionel Hovsepian, et al.
Journal of Diabetes Science and Technology|April 4, 2025
Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor DesignShridhara Alva, Anuj Bhargava, Bruce Bode, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 21, 2020
Breakdown of the Small-Polaron Hopping Model in Higher-Order SpinelsAnuj Bhargava, Roni Eppstein, Jiaxin Sun, et al.
Current Medical Research and Opinion|November 17, 2011
Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world settingRichard M Bergenstal, Louis P Garrison, Lesley-Ann Miller, et al.
Lancet (London, England)|February 28, 2019
Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trialRichard M Bergenstal, Mary Johnson, Rebecca Passi, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|April 19, 2012
Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial)Bruce S Trippe, Mark D Shepherd, Franklin C Coulter, et al.
The American Journal of Medicine|October 27, 2009
A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial)David S Oyer, Mark D Shepherd, Franklin C Coulter, et al.
Clinical Therapeutics|July 12, 2011
Efficacy and tolerability of self-titrated biphasic insulin aspart 70/30 in patients aged >65 years with type 2 diabetes: an exploratory post hoc subanalysis of the INITIATEplus trialDavid S Oyer, Mark D Shepherd, Franklin C Coulter, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|February 2, 2019
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 TrialLouis Chaykin, Anuj Bhargava, Raymond de la Rosa, et al.
NEJM Evidence|June 23, 2025
Semaglutide in Adults with Type 1 Diabetes and ObesityViral N Shah, Halis K Akturk, Davida Kruger, et al.
Diabetes Technology & Therapeutics|December 14, 2019
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical TrialJames Thrasher, Sarit Polsky, Lionel Hovsepian, et al.
Journal of Diabetes Science and Technology|April 4, 2025
Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor DesignShridhara Alva, Anuj Bhargava, Bruce Bode, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 21, 2020
Breakdown of the Small-Polaron Hopping Model in Higher-Order SpinelsAnuj Bhargava, Roni Eppstein, Jiaxin Sun, et al.
Current Medical Research and Opinion|November 17, 2011
Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world settingRichard M Bergenstal, Louis P Garrison, Lesley-Ann Miller, et al.
Lancet (London, England)|February 28, 2019
Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trialRichard M Bergenstal, Mary Johnson, Rebecca Passi, et al.
Pageof 5